MA40388A - Méthodes et compositions permettant de traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale, favoriser l'amincissement, et traiter ou prévenir le développement du diabète - Google Patents

Méthodes et compositions permettant de traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale, favoriser l'amincissement, et traiter ou prévenir le développement du diabète

Info

Publication number
MA40388A
MA40388A MA040388A MA40388A MA40388A MA 40388 A MA40388 A MA 40388A MA 040388 A MA040388 A MA 040388A MA 40388 A MA40388 A MA 40388A MA 40388 A MA40388 A MA 40388A
Authority
MA
Morocco
Prior art keywords
preventing
promoting
treating
compositions
diabetes
Prior art date
Application number
MA040388A
Other languages
English (en)
Other versions
MA40388B1 (fr
Inventor
Gabriel Gojon-Romanillos
Gabriel Gojon-Zorrilla
Original Assignee
Nan Global Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nan Global Llc filed Critical Nan Global Llc
Priority claimed from PCT/US2015/039075 external-priority patent/WO2016004363A2/fr
Publication of MA40388A publication Critical patent/MA40388A/fr
Publication of MA40388B1 publication Critical patent/MA40388B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions et des kits comprenant un découpleur chimique, par exemple la tyrphostine 9 ou un précurseur ou un sel de celle-ci, et des compositions comprenant un découpleur chimique, par exemple la tyrphostine 9 en association avec un ou plusieurs agents thérapeutiques, par exemple la l-carnitine, qui sont utiles, notamment, pour traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale/l'amincissement, et/ou traiter ou prévenir le développement du dia
MA40388A 2014-07-03 2015-07-02 Méthodes et compositions permettant de traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale, favoriser l'amincissement, et traiter ou prévenir le développement du diabète MA40388B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020797P 2014-07-03 2014-07-03
PCT/US2015/039075 WO2016004363A2 (fr) 2014-07-03 2015-07-02 Méthodes et compositions permettant de traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale, favoriser l'amincissement, et traiter ou prévenir le développement du diabète

Publications (2)

Publication Number Publication Date
MA40388A true MA40388A (fr) 2017-05-10
MA40388B1 MA40388B1 (fr) 2023-12-29

Family

ID=89428879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40388A MA40388B1 (fr) 2014-07-03 2015-07-02 Méthodes et compositions permettant de traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale, favoriser l'amincissement, et traiter ou prévenir le développement du diabète

Country Status (1)

Country Link
MA (1) MA40388B1 (fr)

Also Published As

Publication number Publication date
MA40388B1 (fr) 2023-12-29

Similar Documents

Publication Publication Date Title
MX2021015661A (es) Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
EA201890641A3 (ru) Стимуляторы sgc
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
MX2016008096A (es) Tratamiento de superficies de particulas y uso de las mismas.
SG11201705450SA (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
MA43650B1 (fr) Formulations/compositions comprenant un inhibiteur de btk
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MX2017005413A (es) Formas cristalinas de maltol ferrico.
MA40388A (fr) Méthodes et compositions permettant de traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale, favoriser l'amincissement, et traiter ou prévenir le développement du diabète
MX2018011512A (es) Uso de insulina para promover el vaciamiento gástrico.
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
HK1242965A1 (en) Apilimod for use in the treatment of colorectal cancer
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
UA70225U (ru) Применение композиции, содержащей мирамистин, в качестве лекарственного средства для лечения заболеваний горла
SG10201900892SA (en) Composition containing apomorphine and a divalent metal cation
HK1237265A1 (en) Combination therapy compositions and methods for treating cancers